PharmaCyte Biotech Inc (PMCB) stock price

PharmaCyte Biotech Inc (PMCB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.46 (+8.42%), Market cap $0.01B, 52-week low–high $0.63 ~ $1.22.

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technolo

Key metrics

Financial statements, price targets, institutional (13F) holdings and related news for PharmaCyte Biotech Inc are updated in real time on BlackAll Trade.

PharmaCyte Biotech Inc financial summary

Key ratios · profitability · growth

Frequently asked questions

What is the current PharmaCyte Biotech Inc (PMCB) stock price?

PharmaCyte Biotech Inc trades at $0.46 (+8.42%). Real-time quotes and charts are available on BlackAll Trade.

What is the PharmaCyte Biotech Inc (PMCB) market cap?

PharmaCyte Biotech Inc has a market cap of about $0.01B.

What does PharmaCyte Biotech Inc (PMCB) do?

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The